Revenue Performance - Total revenue for Q3 2023 increased by 8.4% to HKD 4,741 million, with HKD 3,915 million from the tissue segment and HKD 826 million from personal care[2] - Total revenue for the nine months ended September 30, 2023, grew by 5.4% to HKD 14,810 million, with HKD 12,276 million from the tissue segment and HKD 2,534 million from personal care[3] Profitability Metrics - Gross profit for Q3 2023 rose by 8.7% to HKD 1,294 million, with a gross margin increase of 0.1 percentage points to 27.3%[2] - Gross profit for the nine months decreased by 11.0% to HKD 3,821 million, with a corresponding gross margin decline of 4.7 percentage points to 25.8%[3] - Operating profit surged by 71.6% to HKD 133 million, with an operating margin increase of 1.0 percentage points to 2.8%[2] - Operating profit for the nine months fell by 67.6% to HKD 270 million, with an operating margin contraction of 4.1 percentage points to 1.8%[3] - EBITDA for Q3 2023 improved by 16.4% to HKD 465 million, with an EBITDA margin increase of 0.7 percentage points to 9.8%[2] Exchange Loss - Total exchange loss for Q3 2023 was HKD 10.7 million, significantly improved from a loss of HKD 54.1 million in Q3 2022[2] Strategic Focus - The company continues to focus on innovation and brand building to sustain competitive advantages and drive profitable growth in key markets[2] Shareholding Information - Essity Aktiebolag (publ) holds approximately 51.59% of the company's issued share capital[3]
维达国际(03331) - 2023 Q3 - 季度业绩